By identifying and targeting context-specific genetic alterations, such as TP53 mutations, ARID1A loss, ATM deficiency, and oncogene-driven RS, clinicians can exploit tumor-specific dependencies while sparing normal cells. This evidence concerns the gene ATM and neoplasm.